HAC of the uterine cervix is very rare and occurs mainly in postmenopausal women, and the first symptom is irregular vaginal bleeding in all cases, with elevated serum AFP values.
First-pass extracted concept
hepatoid adenocarcinoma of the uterine cervix
Aliases
HAC of the cervix, HAC of the uterine cervix
Evidence Snippets
Supporting Sources
Linked Claims
Reported hepatoid adenocarcinoma of the uterine cervix occurs mainly in postmenopausal women and presents with irregular vaginal bleeding and elevated serum AFP.
HAC of the uterine cervix is very rare and occurs mainly in postmenopausal women, and the first symptom is irregular vaginal bleeding in all cases, with elevated serum AFP values.
Hepatoid adenocarcinoma of the cervix is more prone to metastasis and has worse prognosis than ordinary cervical adenocarcinoma.
HAC of the cervix is more prone to metastasis than ordinary cervical adenocarcinoma, and its prognosis is worse.
Hepatoid adenocarcinoma is often associated with elevated serum alpha-fetoprotein.
Hepatoid adenocarcinoma (HAC) is a specific extrahepatic adenocarcinoma with hepatocellular differentiation, often associated with elevated serum alpha-fetoprotein (AFP).
Only two cases of hepatoid adenocarcinoma of the uterine cervix had been reported in the literature at the time of publication.
Only two cases have been reported in the literature
The pathogenesis of hepatoid adenocarcinoma is mainly related to hepatoid differentiation, gene mutation, and inflammatory stimulation.
With the development of molecular pathology and next-generation sequencing technology, the pathogenesis of HAC is mainly related to hepatoid differentiation, gene mutation, and inflammatory stimulation.
Hepatoid adenocarcinoma of the uterine cervix is very rare.
HAC of the uterine cervix is very rare
Treatment of hepatoid adenocarcinoma of the cervix follows cervical cancer surgical management with postoperative radiotherapy or platinum-based combination chemotherapy.
The treatment plan still refers to the surgical treatment plan for cervical cancer, and radiotherapy or platinum-based combination chemotherapy is given after surgery.